肝内胆管癌的诊治进展
| 作者: |
1,2王杰,
1张洪新,
1袁鹏,
1胡龙泉
1 空军军医大学第二附属医院介入疼痛科，西安 710038 2 空军军医大学基础医学院，西安 710032 |
| 通讯: |
袁鹏
Email: yuanpeng834700@126.com 胡龙泉 Email: 616879635@qq.com |
| DOI: | 10.3978/j.issn.2095-6959.2022.10.036 |
| 基金: | 国家自然科学基金(81802345，82172922)；中国博士后科学基金(2020T130787，2019M663984)；空军军医大学第二附属医院国家自然科学基金助推项目计划(2021ZTXM-002)。 |
摘要
Progress in diagnosis and treatment of intrahepatic cholangiocarcinoma
CorrespondingAuthor: YUAN Peng Email: yuanpeng834700@126.com
DOI: 10.3978/j.issn.2095-6959.2022.10.036
Foundation: This work was supported by the National Natural Science Foundation (81802345, 82172922), China Postdoctoral Science Foundation (2020T130787, 2019m663984), and the National Natural Science Foundation, Second Affiliated Hospital of Air Force Military Medical University (2021ZTXM-002), China.
Abstract
Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor that occurs proximal to the segmental biliary ducts, The prognosis of this disease is poor, and the incidence of this disease has continued to increase in recent years. Commonly known risk factors include chronic hepatitis, cirrhosis, biliary inflammatory disease, and hepatobiliary fluke, which are characterized by dull abdominal pain and other nonspecific symptoms. ICC is a highly aggressive malignant tumor, and radical surgical resection is the preferred treatment. In recent years, some progress has been made in the diagnosis and treatment of ICC. Tumor staging methods are constantly updated, and adjuvant chemotherapy, targeted therapy and immunotherapy can also be applied to patients with advanced and metastatic tumors.